Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

ClinicalTrials.gov ID: NCT05032820

Public ClinicalTrials.gov record NCT05032820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMTCTN1902

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).

Study identification

NCT ID: NCT05032820
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Medical College of Wisconsin; Other
Enrollment: 40 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Lenalidomide Drug
bb2121 Biological
Cyclophosphamide Drug
Fludarabine Drug
leukapheresis Procedure

Drug · Biological · Procedure

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 5, 2022 (Actual)
Primary completion: Aug 22, 2024 (Actual)
Completion: Feb 20, 2025 (Actual)
Last update posted: May 19, 2026

2022 – 2025

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010	—
Stanford Hospital and Clinics	Palo Alto	California	94305	—
University of California, San Francisco	San Francisco	California	94143	—
H. Lee Moffitt Cancer Center	Tampa	Florida	33612	—
Loyola University Medical Center	Maywood	Illinois	60153	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Roswell Park Cancer Center	Buffalo	New York	14203	—
Mount Sinai Medical Center	New York	New York	10029	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Duke University Medical Center	Durham	North Carolina	27705	—
University of Pennsylvania Hospital Center	Philadelphia	Pennsylvania	19104	—
Baylor College and Medicine	Houston	Texas	77030	—
University of Virginia	Charlottesville	Virginia	22908	—
University of Wisconsin Hospitals and Clinics	Madison	Wisconsin	53792	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05032820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 19, 2026 · Synced Oct 25, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05032820 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →